Target intelligence / Profile preview

Peptostreptococcal albumin-binding protein (PAB)

Target
PAB
Molecular classification
Bacterial surface protein, Cell-wall anchored protein, Albumin-binding domain protein
01

Overview

Peptostreptococcal albumin-binding protein (PAB) is a cell-surface protein expressed by the anaerobic bacterium *Finegoldia magna* (formerly *Peptostreptococcus magnus*)[2][3]. The protein contains a **GA module**, a 53-amino acid domain composed of a left-handed three-helix bundle structure that binds human serum albumin with strong affinity[2][5]. PAB functions as a virulence factor, enabling the bacterium to bind and coat itself with host albumin, thereby camouflaging itself from immune detection and potentially scavenging protein-bound nutrients[3][4]. The albumin-binding site is located on domain II of the human serum albumin molecule and involves residues primarily in the second helix and surrounding loops of the GA module[2][3]. *Finegoldia magna* strains expressing PAB show increased growth rates and virulence compared to non-expressing strains, and the protein's host specificity reflects the narrow host range of this anaerobic bacterium[4]. While structurally similar to streptococcal protein G, which has broader species specificity, PAB represents an interesting evolutionary example of bacterial adaptation to specific host environments[6][7].

Other names
Protein PABFinegoldia magna albumin-binding protein (the organism was formerly known as Peptostreptococcus magnus)GA module-containing protein (refers to its functional domain)
02

Mechanism of action

Not applicable — this is a bacterial protein, not a drug target.

03

Biological functions

Serum albumin bindingImmune evasion (camouflaging bacteria with host proteins to evade immune recognition)Nutrient scavenging (potentially scavenging protein-bound nutrients)Virulence factor (contributes to pathogenicity)
04

Disease associations

Infection (bacterial pathogenesis in Finegoldia magna infections)Opportunistic infection (associated with anaerobic infections in compromised hosts)
05

Safety considerations

Not applicable in a drug development context. However, the presence of this albumin-binding protein contributes to bacterial virulence and pathogenicity in Finegoldia magna infections[4].
06

Interacting drugs

None documented in the search results. This protein has not been developed as a drug target.
07

Biomarkers

None documented. This protein is not used for patient selection or efficacy monitoring in clinical settings.

Beyond the preview

Go deeper on Peptostreptococcal albumin-binding protein (PAB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptostreptococcal albumin-binding protein (PAB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call